Publications scientifiques

Depuis le 28/07/2025
  1. Oncologists' knowledge, practices and ethical opinions about therapeutic misconception: a French national survey.
    Haaser T, Clair S, Marty S, Berdai D, Hoarau H, Saux MC, Dreyfuss D, Maternowski PJ.
    BMC Med Ethics. 2025
  2. Experimental protocols and models for assessing the permeation of antineoplastic drugs through gloves: From a scoping review to a guidelines proposition for future studies.
    Swierczynski G, Guyon J, Molimard M, Garrigou A, Baldi I, Verdun-Esquer C, Villa A, Canal-Raffin M.
    J Hazard Mater. 2025
  3. Characteristics of Drug-RElated Hospitalizations for Nursing HOme Residents: Cross-Sectional RENHO Study.
    Lopez A, Alfarano C, Lepetit M, Chebane L, Redjimi N, Couret A, Fabre D, Gardette V, Berdaï D, Lapeyre-Mestre M, Bagheri H.
    Drug Saf. 2025
  4. Impact of cardiac rehabilitation and treatment compliance after ST-segment elevation myocardial infarction (STEMI) in France, the STOP SCA+ study.
    Laurent E, Godillon L, Tassi MF, Marcollet P, Chassaing S, Decomis M, Bezin J, Laure C, Angoulvant D, Range G, Grammatico-Guillon L.
    Front Cardiovasc Med. 2025
  5. Use and Potential Misuse of GLP-1 Receptor Agonists in France: a Nationwide Cohort Study.
    du Soulier N, Pariente A, Bezin J, Grenet G, Faillie JL, de Germay S.
    Value Health. 2025
  6. Correction: Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database.
    Di Napoli R, Richez C, Scavone C, Singier A, Demourgues M, Mascolo A, Capuano A, Salvo F.
    Drug Saf. 2025
  7. Letter to the Editor from Raschi et al.: "Endocrine adverse reactions of tyrosine kinase inhibitors in combination with immune checkpoint inhibitors".
    Raschi E, Donati M, Salvo F, Khouri C.
    J Clin Endocrinol Metab. 2025
  8. Contribution of Addictovigilance data to assess adverse-events linked to psychoactive substances in children and adolescents.
    Peyrière H, Batisse A, Sam-Laï NF, Daveluy A, Fournier-Choma C, Deheul S, Chevalier C, Lacroix C, Gibaja V, Aquizerate A, Pain S, Jouanjus E, Picot MC, Nogue E.
    Br J Clin Pharmacol. 2025
  9. Medication errors in malaria management in children: insights from pharmacovigilance data in the Democratic Republic of Congo.
    Amba MN, Ntambwe EK, Biongo AE, Ntamabyaliro N, Kahunu GM, Mabiala JB, Ndosimao CN, Lutete GT, Miremont-Salamé G, Fourrier-Réglat A.
    BMC Pharmacol Toxicol. 2025
  10. Effect of the COVID-19 epidemic on the association between antihypertensive drug interruption and the risk of major cardiovascular event in France.
    Mathieu C, Bezin J, Pariente A.
    Am J Hypertens. 2025
  11. Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure Patients: A Nationwide Population-Based Cohort Study.
    Gautier P, Elbaz M, Bezin J, Delmas C, Cherbi M, Bouisset F, Vindis C, Renoux A, Lafaurie M, Montastruc F.
    JACC Heart Fail. 2025
  12. Correction: Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database.
    Di Napoli R, Richez C, Scavone C, Singier A, Demourgues M, Mascolo A, Capuano A, Salvo F.
    Drug Saf. 2025
  13. The safety profile of fluoroquinolones.
    Jonville-Béra AP, Largeau B, di Meglio F, Pariente A.
    Infect Dis Now. 2025
  14. Interplay of Spontaneous Reporting and Longitudinal Healthcare Databases for Signal Management: Position Statement from the Real-World Evidence and Big Data Special Interest Group of the International Society of Pharmacovigilance.
    Crisafulli S, Bate A, Brown JS, Candore G, Chandler RE, Hammad TA, Lane S, Maro JC, Norén GN, Pariente A, Russom M, Salas M, Segec A, Shakir S, Spini A, Toh S, Tuccori M, van Puijenbroek E, Trifirò G; Real-World Evidence and Big Data Special Interest Group of the International Society of Pharmacovigilance.
    Drug Saf. 2025
  15. The latest updates on the proper use of fluoroquinolones - Actualisation 2025 update by the SPILF and the GPIP.
    Vuotto F, Bru JP, Canaoui E, Caseris M, Chopin MCC, Cohen R, Diamantis S, Dihn A, Fillatre P, Gauzit R, Gillet Y, Jonville-Bera AP, Lafaurie M, Lesprit P, Lorrot M, Lourtet J, Maulin L, Poitrenaud D, Pariente A, Raymond J, Strady C, Stahl JP, Varon E, Welker Y, Bonnet E.
    Infect Dis Now. 2025
  16. Gloves Standards and Occupational Exposure to Antineoplastic Drugs in the European Context.
    Swierczynski G, Canal-Raffin M, Tuduri L.
    Health Sci Rep. 2025
  17. Changes in the Ambulatory Use of Antibiotics in France Due to the COVID-19 Pandemic in 2020-2022: A Nationwide Time-Series Analysis.
    Rousselot N, Brayan T, Dumartin C, Clément M, Pariente A.
    Ann Fam Med. 2025
  18. Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database.
    Di Napoli R, Richez C, Scavone C, Singier A, Demorgues M, Mascolo A, Capuano A, Salvo F.
    Drug Saf. 2025
  19. Second primary cancers and hormonal therapies for prostate cancer: A nested case-control study.
    Scailteux LM, Bezin J, Gundelwein M, Edeline J, Oger E, Balusson F, Pariente A.
    Fundam Clin Pharmacol. 2025
  20. Guidelines and Best Practices for the Use of Targeted Maximum Likelihood and Machine Learning When Estimating Causal Effects of Exposures on Time-To-Event Outcomes.
    Talbot D, Diop A, Mésidor M, Chiu Y, Sirois C, Spieker AJ, Pariente A, Noize P, Simard M, Luque Fernandez MA, Schomaker M, Fujita K, Gnjidic D, Schnitzer ME.
    Stat Med. 2025